Mobia Medical, Inc. (MOBI) Competitive Analysis & Comparison (2026)

Quality vs Value comparison of Mobia Medical, Inc. (MOBI) and competitors
Company	Ticker	Quality Score	Value Score	Classification
Mobia Medical, Inc.	MOBI	53%	90%	High Quality
NeuroPace, Inc.	NPCE	40%	30%	Underperform
BrainsWay Ltd.	BWAY	67%	80%	High Quality
CVRx, Inc.	CVRX	47%	50%	Value Play
electroCore, Inc.	ECOR	13%	20%	Underperform
Neuronetics, Inc.	STIM	27%	30%	Underperform

Mobia Medical, Inc. (MOBI) occupies a highly specialized and structurally advantageous niche within the medical device industry, focusing uniquely on active therapeutic neurostimulation for stroke rehabilitation. Unlike many of its peers that crowd into the highly saturated pain management, sleep apnea, or major depressive disorder markets, MOBI's Vivistim system stands largely alone as an FDA-approved implantable device for upper limb motor function recovery. This lack of direct, surgically implantable competition provides the company with a massive total addressable market (TAM) of stroke survivors and a defensible commercial runway that sets it apart from non-invasive therapy makers. Financially, MOBI's profile is a classic early-stage, high-growth medical technology story. The company commands a market capitalization of roughly $410M while delivering explosive top-line revenue growth that recently exceeded +100% year-over-year, hitting $12.07M in its latest quarter. This hyper-growth commands a premium valuation relative to its current sales, a stark contrast to older, legacy small-cap competitors that have stagnated in growth and consequently trade at deep discounts. MOBI is currently rewarded by the market purely for its market capture momentum rather than its bottom-line efficiency. However, when compared to the broader competition, MOBI's risk profile remains highly elevated due to its substantial cash burn and deep unprofitability. The company reported a staggering negative EPS, underscoring the immense capital expenditures required to commercialize an implantable medical device, build a specialized sales force, and navigate post-market clinical registries. While profitable or mature peers offer a margin of safety for risk-averse investors, MOBI appeals exclusively to growth-oriented retail investors willing to absorb significant near-term volatility and potential equity dilution in exchange for long-term market dominance.

NeuroPace, Inc. (NPCE) is a direct, formidable competitor to Mobia Medical, Inc. (MOBI) within the specialized implantable neuromodulation space, though it targets epilepsy rather than stroke recovery. NPCE commands a slightly larger market capitalization of $539M compared to MOBI's $410M. While NPCE benefits from a much more mature commercial infrastructure and a predictable base of $100M in annual revenue, its top-line momentum is slower. Conversely, MOBI boasts explosive early-stage growth but carries significantly higher execution risks as it attempts to scale its newly approved Vivistim platform. Investors must weigh NPCE's operational stability against MOBI's aggressive early market capture. In Business & Moat, NPCE holds a slight edge in brand recognition given its longer tenure in the epilepsy market. Switching costs heavily favor both companies equally; as surgically implanted devices, their functional tenant retention is nearly 100%. (Switching costs measure the financial and physical barriers to changing a product; in medtech, an implanted device represents a 100% retention benchmark, making it a near-perfect moat). Scale favors NPCE, which supports a much larger installed base of active patients. Network effects are virtually nonexistent for both device makers, though NPCE has a slight registry data advantage. Regulatory barriers act as permitted sites; both hold elite FDA PMA approvals. (FDA PMAs function like zoning permits that lock out competitors; obtaining one is a multi-year benchmark that proves an immense competitive moat). Other moats include extensive proprietary algorithms for NPCE. Winner overall for Business & Moat: NPCE, primarily due to its established scale and proven surgical center penetration. In Financial Statement Analysis, MOBI dominates head-to-head revenue growth with a >100% surge versus NPCE's 25%. (Revenue growth reflects market adoption; the medtech benchmark for early-stage success is >20%, making MOBI exceptional). NPCE takes the gross margin edge at 77.2% versus MOBI's ~75%. (Gross margin is the profit left after paying to make the device; the industry benchmark is >70%). Operating and net margins are deeply negative for both, though NPCE is closer to breakeven. For ROE/ROIC, both are negative, though NPCE destroys less equity per dollar. (ROE shows how effectively investor money is turned into profit; a positive figure is the benchmark). Liquidity favors NPCE with roughly $61.1M in cash maintaining a healthy current ratio. (Liquidity shows if a company can pay immediate bills; a ratio >1.5x is the standard benchmark). Net debt/EBITDA is effectively N/A as both lack positive EBITDA. (This measures debt against cash earnings; <3.0x is preferred). Interest coverage is similarly negative (N/A) for both. FCF/AFFO is heavily negative across the board. Payout/coverage is 0% as neither pays dividends. Overall Financials Winner: NPCE, owing to its superior liquidity and narrower operating losses. In Past Performance, looking at the 2024-2026 window, NPCE shows a 1y revenue CAGR of 25%, while MOBI boasts >100%. (CAGR is the smoothed-out annual growth rate; higher is always better). Margin trends favor NPCE, which expanded gross margins to 77.2%. In terms of TSR incl. dividends, MOBI has a slight edge with +8% recent returns versus NPCE's -7% year-over-year slide. (TSR tracks total stock price gains plus dividends; positive benchmarks vary by market cycle). Risk metrics highlight NPCE as the safer bet; its volatility/beta is lower than MOBI's highly volatile trading history. (Beta measures stock swings vs the market; a benchmark of 1.0 means average risk). NPCE's max drawdown was steep historically but is now stabilizing. Winner for growth: MOBI. Winner for margins: NPCE. Winner for TSR: MOBI. Winner for risk: NPCE. Overall Past Performance Winner: NPCE, because its historical baseline is much more established and derisked. For Future Growth, TAM/demand signals point heavily toward MOBI, as stroke recovery represents a massive, largely untapped surgical market compared to the crowded epilepsy space. Pipeline & pre-leasing (analogous to pre-surgical center onboarding) favors NPCE, which anticipates a new IGE label expansion by late 2026. Yield on cost (functioning as R&D yield in medtech) leans toward MOBI, which generates higher incremental sales per R&D dollar spent. (Yield on cost measures profit generated per invested dollar; higher R&D yield shows superior innovation efficiency). Pricing power is roughly even, as both hold unique FDA breakthrough designations allowing premium reimbursement. Cost programs give NPCE an edge, as management explicitly targets operating breakeven. Refinancing/maturity wall risks hurt NPCE slightly due to existing debt facilities. ESG/regulatory tailwinds are essentially even. Overall Growth outlook winner: MOBI, with the primary risk being a failure to secure broad insurance reimbursement fast enough. Valuation metrics reflect two entirely different company lifecycles. P/AFFO is negative for both, so it sits at N/A. (P/AFFO prices cash flow; impossible to calculate without positive cash generation). EV/EBITDA is similarly N/A due to operating losses. (EV/EBITDA values the business against cash earnings; 10x-15x is normal). P/E is also N/A for both. The implied cap rate (cash yield) is mathematically 0% for both. Looking at NAV premium/discount (measured via Price-to-Sales for pre-profit firms), NPCE trades at a reasonable 5.3x forward sales, while MOBI demands a hefty premium of roughly 8.5x. (Lower multiples mean cheaper valuation; NPCE trades near the sector average while MOBI commands a high premium). Dividend yield & payout/coverage are securely 0%. Quality vs price note: NPCE offers a derisked, mature pipeline at a lower multiple, whereas MOBI demands a strict growth premium. Better value today: NPCE, due to its heavily discounted price-to-sales ratio relative to its gross margin profile. Winner: NPCE over MOBI for the risk-conscious retail investor. While MOBI is capturing headlines with explosive >100% revenue growth and a massive stroke rehabilitation TAM, NPCE offers a far more stable financial foundation with $100M in revenue, superior 77.2% gross margins, and lower stock volatility. MOBI's key weaknesses—namely a staggering negative EPS and an expensive 8.5x price-to-sales multiple—make it highly vulnerable to market corrections if execution falters. Ultimately, NPCE's established foothold and clear path to profitability provide a vastly superior risk-adjusted investment.

BrainsWay Ltd. (BWAY) operates in the non-invasive side of neuromodulation, directly contrasting with MOBI's surgically implanted Vivistim device. With a market capitalization of $588M, BWAY has successfully transitioned into outright profitability, a rare feat in the small-cap medtech universe. MOBI, meanwhile, is burning significant cash to establish its stroke recovery market. While BWAY lacks the immense hardware moats of an implantable device, its sheer financial health makes it a formidable point of comparison, offering stability where MOBI offers aggressive, unproven upside. In Business & Moat, BWAY has high brand recognition in the Deep TMS depression space, whereas MOBI is just pioneering the stroke niche. Switching costs severely favor MOBI; as a surgical implant, its functional tenant retention is nearly 100%. (Switching costs are the hurdles to changing products; 100% retention is the ultimate moat benchmark). BWAY relies on clinic-based recurring sessions, which have lower patient lock-in. Scale goes to BWAY with an installed base of 1,820 systems globally. Network effects are minimal for both. Regulatory barriers are high for both due to FDA clearances, acting as restrictive permitted sites. (A benchmark hurdle preventing easy competition). Other moats include BWAY's proprietary H-coil technology. Winner overall for Business & Moat: MOBI, because surgical implants create permanent customer lock-in that BWAY's clinic-based hardware simply cannot match. In Financial Statement Analysis, MOBI's >100% revenue growth beats BWAY's 35%. (Revenue growth above 20% shows extreme demand). Gross margin shows BWAY holding steady at 75%, roughly equal to MOBI's ~75%. (Gross margin shows profit after manufacturing; 70% is standard). For operating and net margins, BWAY crushes MOBI with a positive net income of $2.3M against MOBI's massive losses. (Net margin shows bottom-line profitability; positive margins are rare and highly prized here). ROE/ROIC for BWAY is positive, instantly besting MOBI's negative returns. (ROE measures the efficiency of shareholder capital). Liquidity favors BWAY, flush with $58.9M in cash, maintaining a current ratio well above the 1.5x benchmark. (Liquidity measures the ability to pay short-term bills). Net debt/EBITDA is robust for BWAY as it generated positive $2.8M adjusted EBITDA, while MOBI is N/A. Interest coverage is safe for BWAY; MOBI is negative. FCF/AFFO is positive for BWAY. Payout/coverage: Both 0%. Overall Financials winner: BWAY, driven entirely by its rare, positive net income and EBITDA. For Past Performance, looking at 2023-2026, BWAY's revenue CAGR sits at a respectable ~20%, while MOBI boasts >100%. (CAGR smooths multi-year growth; higher is better). Margin trend shows BWAY maintained flat 75% margins (0 bps change), whereas MOBI is aggressively improving from a lower base. In TSR incl. dividends, BWAY rocketed +239% over the past year, completely destroying MOBI's +8%. (TSR reflects total investor returns). Risk metrics show BWAY with a beta of 1.05, making it less volatile than MOBI's 1.50. (Beta of 1.0 is average risk). BWAY's max drawdown was steep historically but has fully recovered. Winner for growth: MOBI. Winner for margins: BWAY. Winner for TSR: BWAY. Winner for risk: BWAY. Overall Past Performance winner: BWAY, backed by an unstoppable 239% one-year stock return. In Future Growth, TAM/demand signals favor MOBI's untouched stroke market over BWAY's increasingly crowded depression space. Pipeline & pre-leasing (pre-surgical/pre-install pipeline): BWAY shipped a record 117 systems in Q1, showing massive momentum. Yield on cost (R&D yield): BWAY proves superior efficiency, converting R&D directly into $2.0M in operating income. (Yield on cost measures the operating profit generated per dollar of investment; positive yield beats the industry benchmark). Pricing power: MOBI holds the edge as a unique surgical intervention without direct therapeutic substitutes. Cost programs: BWAY has successfully optimized its SG&A to achieve profitability. Refinancing/maturity wall: BWAY has no immediate wall thanks to its cash generation. ESG/regulatory tailwinds: BWAY expands access to non-drug mental health care. Overall Growth outlook winner: BWAY, with the primary risk being increased competition from alternative non-invasive treatments. Fair Value metrics showcase a stark contrast. BWAY generates real earnings, giving it a forward P/E of roughly 63x, whereas MOBI's P/E is N/A. (The Price-to-Earnings ratio measures how much investors pay per dollar of profit; 63x shows a high growth premium). EV/EBITDA for BWAY sits around 50x, while MOBI is N/A. (EV/EBITDA values the entire business against cash profits). P/AFFO is N/A for both due to differing accounting standards. Implied cap rate is minimal for BWAY and 0% for MOBI. NAV premium/discount (measured via Price-to-Sales): BWAY trades at a 10x sales multiple, slightly pricier than MOBI's 8.5x. Dividend yield & payout/coverage is 0% for both. Quality vs price note: BWAY's valuation premium is entirely justified by its positive cash flow and derisked business model. Better value today: BWAY, because paying for actual earnings is vastly safer than paying for a cash-burning promise. Winner: BWAY over MOBI based on undeniable financial superiority and proven execution. While MOBI commands an exciting monopoly in implantable stroke recovery with an impressive >100% revenue jump, BWAY has achieved the holy grail for small-cap medtech: outright profitability, marked by $2.3M in net income and $2.8M in EBITDA. MOBI's notable weakness is its steep cash burn, posing severe dilution risks to retail investors. BWAY's robust 239% one-year stock return and rock-solid balance sheet make it the definitive, lower-risk winner in this comparison.

CVRx, Inc. (CVRX) represents a direct implantable neuromodulation peer to MOBI, but it utilizes its Barostim technology to treat cardiovascular diseases rather than neurological rehabilitation. With a market cap of $148M, CVRX has struggled heavily in the public markets, trading at a fraction of MOBI's $410M valuation. While CVRX boasts higher absolute revenue and world-class gross margins, its top-line growth has decelerated significantly, alarming investors. MOBI represents the opposite spectrum: higher perceived growth and market excitement, but significantly less commercial maturity. For Business & Moat, both companies rely on the heavy switching costs inherent to surgical implants; device removal is rare, so tenant retention is functionally near 100%. (Switching costs measure customer lock-in; near 100% retention is the benchmark for maximum defensibility). Brand favors CVRX, which has established Barostim in 252 active implanting centers. Scale also tilts to CVRX due to its higher geographic reach. Network effects are weak for both. Regulatory barriers serve as permitted sites; both possess the gold standard FDA PMA. (FDA PMA approval is the strictest benchmark in medtech, taking years to clear). Other moats include their respective proprietary IP. Winner overall for Business & Moat: CVRX, primarily due to its higher active center count and established cardiovascular footprint. In Financial Statement Analysis, MOBI easily wins on revenue growth with a >100% surge against CVRX's sluggish 4% to 10% expansion. (Revenue growth tracks product adoption; falling below the 20% benchmark signals market saturation for a small cap). CVRX dominates gross margins at 85% versus MOBI's ~75%. (Gross margin is profit after manufacturing; 85% is elite against the 70% benchmark). Operating/net margins are deeply negative for both, with CVRX posting an EPS of -$2.02. ROE/ROIC is negative for both. (ROE measures return on investor cash; negative metrics are common but undesirable). Liquidity strongly favors CVRX, marked by an exceptional 10.2x current ratio. (The current ratio measures short-term solvency; 10.2x easily beats the 1.5x benchmark). Net debt/EBITDA is N/A due to negative EBITDA. Interest coverage is negative. FCF/AFFO is a heavy burn for both. Payout/coverage is 0%. Overall Financials winner: MOBI, because in cash-burning medtech, growth must remain high to justify the losses. In Past Performance, reviewing 2024-2026, CVRX's 1y revenue CAGR sits around 10%, while MOBI is compounding at >100%. (CAGR is the smoothed annual growth rate). Margin trends favor CVRX, which pushed its gross margin up +200 bps to 85%. In TSR incl. dividends, MOBI returned +8% while CVRX wiped out shareholder wealth with a -12% return over the past year. (TSR includes stock gains and dividends). Risk metrics are brutal for CVRX; despite a beta of 1.23, it suffered a max drawdown of over -80% from its highs. MOBI's beta is higher at 1.50, but its recent trend is upward. Winner for growth: MOBI. Winner for margins: CVRX. Winner for TSR: MOBI. Winner for risk: MOBI (by virtue of recent momentum). Overall Past Performance winner: MOBI. For Future Growth, TAM/demand signals point to MOBI; stroke recovery is an uncrowded surgical niche, whereas CVRX faces intense pharmaceutical and device competition in heart failure. Pipeline & pre-leasing (pre-surgical onboarding) favors CVRX, which recently initiated the massive BENEFIT-HF randomized trial. Yield on cost (R&D yield) clearly favors MOBI, generating exponentially more revenue growth per invested dollar. (R&D yield shows innovation efficiency; higher is better). Pricing power belongs to CVRX with its 85% margins. Cost programs: CVRX is tightening expenses to offset slow growth. Refinancing/maturity wall: CVRX just amended a loan facility up to $100M, providing runway. ESG/regulatory tailwinds are even. Overall Growth outlook winner: MOBI, with the main risk being the high cost of acquiring new surgeons. Valuation analysis (Fair Value) reveals CVRX as a deeply distressed asset. P/E and EV/EBITDA are both N/A due to operating losses. (P/E measures price per profit dollar; EV/EBITDA measures firm value against cash earnings). P/AFFO is N/A and implied cap rate is 0%. The true differentiator is NAV premium/discount (measured by Price-to-Sales): CVRX trades at a rock-bottom 2.5x sales multiple, while MOBI commands a rich 8.5x premium. (A lower multiple implies a cheaper stock). Dividend yield & payout/coverage are 0% for both. Quality vs price note: CVRX is a classic value trap—cheap but struggling to grow—whereas MOBI is priced for perfection. Better value today: CVRX, strictly on a risk-adjusted multiple basis. Winner: MOBI over CVRX based on vastly superior top-line momentum and market sentiment. While CVRX offers a heavily discounted valuation and world-class 85% gross margins, its anemic 4% quarterly revenue growth is a massive red flag for a cash-burning medtech firm. MOBI's primary weakness is its expensive 8.5x sales multiple, but its >100% revenue growth proves it is successfully executing its commercial rollout. For investors, MOBI's market capture justifies the premium over CVRX's stagnant, distressed profile.

electroCore, Inc. (ECOR) develops non-invasive vagus nerve stimulation (nVNS) therapies, making it a conceptual cousin to MOBI's implantable VNS system. However, ECOR is a micro-cap company valued at roughly $82M, significantly smaller than MOBI's $410M. While ECOR has found recent momentum by pivoting into consumer wellness and broader clinical applications, it lacks the high barriers to entry inherent in MOBI's surgical devices. This comparison highlights the tradeoff between a high-volume, low-margin non-invasive business (ECOR) versus a low-volume, high-margin surgical business (MOBI). In Business & Moat, MOBI holds a definitive advantage. Switching costs for ECOR's handheld devices are minimal, whereas MOBI's surgically implanted Vivistim essentially guarantees 100% tenant retention. (Switching costs measure customer stickiness; surgical implants represent the ultimate benchmark for preventing churn). Brand awareness in the clinical space favors MOBI's breakthrough stroke application, while ECOR's gammaCore relies on a fragmented headache and wellness market. Scale slightly favors ECOR's manufacturing volume due to the handheld nature of its product, but revenue scale favors MOBI. Regulatory barriers are steep for MOBI (FDA PMA) but lower for ECOR's 510(k) and consumer clearances, representing much easier permitted sites for competitors. (FDA PMA is a multi-year benchmark that firmly locks out cheap competition). Winner overall for Business & Moat: MOBI, because implantable devices offer permanent customer capture. Financial Statement Analysis shows MOBI leading in top-line expansion with >100% revenue growth compared to ECOR's estimated ~30% growth on $34.9M TTM revenue. (Revenue growth dictates market share gains; the medtech benchmark is >20%). Gross margins favor MOBI's ~75% surgical premium over ECOR's ~70% consumer-heavy profile. (Gross margin is profit after manufacturing; 70% is standard). Operating/net margins are deeply negative for both, with ECOR posting an EPS of -$1.77. ROE/ROIC are both heavily negative. (ROE measures equity efficiency). Liquidity favors ECOR, which maintains a clean balance sheet with a solid current ratio. (Current ratio checks short-term solvency against a 1.5x benchmark). Net debt/EBITDA is N/A for both due to cash burn. Interest coverage is negative. FCF/AFFO is negative across the board. Payout/coverage is 0%. Overall Financials winner: MOBI, as its gross margin profile and top-line trajectory are superior. Past Performance tells a tale of two volatile stocks. For the 2024-2026 window, ECOR's revenue CAGR is strong, but MOBI's >100% is superior. (CAGR tracks smoothed multi-year growth). Margin trends are relatively flat (0 bps change) for both companies as they scale. In terms of TSR incl. dividends, ECOR has been a massive winner recently, skyrocketing +131% over the past year, easily beating MOBI's +8%. (TSR measures stock price returns). Risk metrics, however, are extreme for ECOR, which trades as a highly speculative micro-cap with massive historical drawdowns and high beta. (Beta measures market volatility; ECOR swings wildly compared to the 1.0 benchmark). Winner for growth: MOBI. Winner for margins: MOBI. Winner for TSR: ECOR. Winner for risk: MOBI. Overall Past Performance winner: ECOR, based purely on its recent 131% stock momentum. Looking at Future Growth, TAM/demand signals strongly favor MOBI; stroke recovery is a massive unmet clinical need, whereas the migraine and wellness markets ECOR targets are flooded with cheap alternatives and pharmaceuticals. Pipeline & pre-leasing (pre-surgical adoption) points to MOBI's growing hospital onboarding. Yield on cost (R&D yield) favors MOBI, generating higher absolute dollars per R&D spend. (R&D yield shows innovation efficiency). Pricing power heavily favors MOBI's surgical reimbursement codes over ECOR's out-of-pocket consumer model. Cost programs are a focus for both to reduce cash burn. Refinancing/maturity wall risks are high for both as they rely on equity markets. ESG/regulatory tailwinds are even. Overall Growth outlook winner: MOBI, with the primary risk being hospital procurement delays. Fair Value metrics highlight ECOR as the cheaper, albeit riskier, asset. Both have an N/A P/E and N/A EV/EBITDA due to unprofitability. (P/E measures price against profit; EV/EBITDA measures firm value against cash earnings). P/AFFO is N/A and the implied cap rate is 0%. Looking at NAV premium/discount (measured via Price-to-Sales), ECOR trades at a modest ~2.3x multiple, while MOBI commands a steep 8.5x multiple. (A lower Price-to-Sales multiple indicates a cheaper valuation). Dividend yield & payout/coverage is 0% for both. Quality vs price note: ECOR is a cheap, speculative micro-cap, whereas MOBI is a premium-priced clinical leader. Better value today: ECOR, strictly for investors seeking a low-multiple entry point. Winner: MOBI over ECOR due to its vastly superior competitive moat and structural pricing power. While ECOR has rewarded recent investors with an incredible 131% TSR and trades at a cheaper valuation, its reliance on the highly competitive, non-invasive consumer wellness market offers little long-term defensibility. MOBI's key strengths lie in its surgical ~75% margins, guaranteed patient retention, and massive >100% revenue growth. Despite MOBI's steep valuation, its FDA-approved implantable platform is fundamentally a much higher-quality asset.

Neuronetics, Inc. (STIM) is a commercial-stage medical technology company targeting psychiatric disorders via its NeuroStar TMS platform. With a battered market capitalization of just $85M and a stock price hovering near $1.29, STIM represents a distressed asset within the broader neuromodulation sector. MOBI, valued at $410M, is experiencing the exact opposite trajectory, riding a wave of clinical excitement and hyper-growth. This comparison pits a rapidly ascending stroke recovery pioneer against a legacy depression-treatment company struggling to find its footing. In Business & Moat, STIM has strong historical brand awareness, boasting the largest clinical data set in major depression for any TMS system. However, MOBI dominates in switching costs; Vivistim is surgically implanted (effectively 100% tenant retention), whereas STIM relies on patients returning to clinics for external sessions. (Switching costs measure patient lock-in; surgical implants are the ultimate benchmark for preventing churn). Scale favors STIM's massive footprint of delivered treatments, but Network effects are minimal for both. Regulatory barriers are high for both (acting as permitted sites), though MOBI's FDA PMA is a higher hurdle than STIM's 510(k) clearances. (FDA clearance benchmarks dictate how easily competitors can enter the space). Winner overall for Business & Moat: MOBI, because its surgical nature creates an unbreakable customer relationship. Financial Statement Analysis underscores STIM's deep struggles. In revenue growth, MOBI's >100% completely eclipses STIM's flat-to-negative growth trajectory. (Revenue growth indicates market vitality; falling below 0% is a severe red flag against the 20% early-stage benchmark). Gross margins are tied at roughly 75% for both. (Gross margin shows profit after manufacturing). Operating and net margins are heavily negative for both. ROE/ROIC is abysmal across the board. (ROE measures equity efficiency; negative numbers show wealth destruction). Liquidity is a major concern for STIM, which recently saw its CFO resign, threatening its current ratio stability. (Current ratio checks short-term solvency against a 1.5x benchmark). Net debt/EBITDA is N/A for both due to cash burn. Interest coverage is negative. FCF/AFFO is negative. Payout/coverage is 0%. Overall Financials winner: MOBI, because its losses are at least funding massive top-line expansion, whereas STIM is shrinking. Past Performance reflects STIM's catastrophic decline. Over the 2021-2026 window, STIM's revenue CAGR is roughly 0%, while MOBI's is skyrocketing. (CAGR tracks smoothed multi-year growth). Margin trends are stagnant (0 bps change) for STIM. In TSR incl. dividends, STIM has plummeted -58.9% over the past year, compared to MOBI's +8% gain. (TSR measures stock price returns). Risk metrics show STIM is in crisis mode, facing immense volatility and activist shareholders demanding a sale of the business. (Beta measures market volatility; STIM's distress causes erratic swings well above the 1.0 benchmark). Winner for growth: MOBI. Winner for margins: Tie. Winner for TSR: MOBI. Winner for risk: MOBI. Overall Past Performance winner: MOBI, as STIM has consistently destroyed shareholder value. Looking at Future Growth, TAM/demand signals strongly favor MOBI's wide-open stroke market over STIM's highly saturated depression space (which includes heavy competition from BWAY). Pipeline & pre-leasing (pre-surgical onboarding) favors MOBI's hospital rollout. Yield on cost (R&D yield) is highly negative for STIM, as R&D spending fails to generate new sales growth. (R&D yield shows innovation efficiency). Pricing power favors MOBI due to lack of direct competitors. Cost programs are the only growth vector for STIM, which is trying to cut costs to survive. Refinancing/maturity wall risks are severe for STIM, leading activists to call for strategic alternatives. ESG/regulatory tailwinds are even. Overall Growth outlook winner: MOBI, with the primary risk being a slow ramp in hospital adoptions. Fair Value metrics highlight STIM as a potential distress/value play. P/E and EV/EBITDA are both N/A due to lack of profits. (P/E measures price against profit; EV/EBITDA measures firm value against cash earnings). P/AFFO is N/A and the implied cap rate is 0%. Looking at NAV premium/discount (measured via Price-to-Sales), STIM trades at an incredibly cheap ~1.2x multiple, compared to MOBI's expensive 8.5x. (A lower Price-to-Sales multiple indicates a cheaper valuation). Dividend yield & payout/coverage is 0% for both. Quality vs price note: STIM is a deeply distressed asset facing a potential fire sale, while MOBI is priced for hyper-growth. Better value today: STIM, strictly as an activist-driven value arbitrage. Winner: MOBI over STIM by a wide margin. While STIM trades at a bargain-basement 1.2x sales multiple and boasts a vast historical treatment footprint, the company is functionally in distress, highlighted by a -58.9% stock drop and activist demands for a sale. MOBI's key strengths—explosive >100% revenue growth and an unbreakable surgical moat—make it a vastly superior fundamental business. Despite MOBI's high cash burn, it is capturing market share, whereas STIM is struggling simply to survive.

Saluda Medical (SLD.AX) is an Australian-listed medtech firm that recently went public to commercialize its Evoke closed-loop spinal cord stimulation (SCS) system for chronic pain. Valued near A$400M (roughly $250M USD) following a brutal 45% drop on its IPO debut, SLD serves as a perfect peer to MOBI. Both are newly commercializing advanced, surgically implanted neuromodulation devices. However, SLD is attempting to disrupt the highly saturated, hyper-competitive chronic pain market, whereas MOBI is creating an entirely new category in stroke recovery. In Business & Moat, both companies boast the ultimate switching costs; their implanted devices ensure functional tenant retention near 100%. (Switching costs measure customer stickiness; surgical implants represent the gold standard for preventing churn). Brand awareness is nascent for both, though SLD has strong clinical backing for its closed-loop technology. Scale is similarly early-stage. Network effects are minimal. Regulatory barriers are immense for both, functioning as elite permitted sites via FDA PMA approvals. (FDA PMA is a multi-year benchmark that firmly locks out cheap competition). Other moats include SLD's real-time neural biomarker reading technology. Winner overall for Business & Moat: Tie, as both possess world-class IP and permanent surgical lock-in. Financial Statement Analysis shows two companies burning cash to scale. In revenue growth, SLD forecasts roughly $81.9M for FY26, representing strong growth, but MOBI's recent >100% quarterly jump indicates faster relative momentum. (Revenue growth indicates market adoption; the medtech benchmark is >20%). Gross margins are roughly equal at ~70-75% for both. (Gross margin is profit after manufacturing; 70% is standard). Operating/net margins are deeply negative as both build out expensive sales forces. ROE/ROIC are heavily negative. (ROE measures equity efficiency; negative numbers show necessary early-stage wealth destruction). Liquidity favors SLD immediately post-IPO, having raised A$231M. (Current ratio checks short-term solvency against a 1.5x benchmark). Net debt/EBITDA is N/A for both due to cash burn. Interest coverage is negative. FCF/AFFO is a heavy burn for both. Payout/coverage is 0%. Overall Financials winner: SLD, purely due to its freshly fortified post-IPO balance sheet. Past Performance centers entirely on recent public market reception. For the 2025-2026 window, SLD's TSR incl. dividends is a disastrous -45% following its debut, punishing early investors. MOBI, meanwhile, has posted a +8% recent gain. (TSR measures stock price returns). Margin trends are flat for both (0 bps change) as they scale. Risk metrics show extreme volatility for SLD, which proved highly susceptible to market skepticism regarding capital-intensive healthcare names. (Beta measures market volatility; early IPOs suffer from erratic swings well above the 1.0 benchmark). MOBI's risk profile is high, but the market has absorbed it better. Winner for growth: MOBI. Winner for margins: Tie. Winner for TSR: MOBI. Winner for risk: MOBI. Overall Past Performance winner: MOBI, having avoided the disastrous IPO collapse that plagued SLD. Looking at Future Growth, TAM/demand signals strongly favor MOBI; stroke recovery is an uncrowded surgical niche, whereas SLD must battle multi-billion-dollar giants (Medtronic, Abbott, Boston Scientific) in the SCS pain market. Pipeline & pre-leasing (pre-surgical onboarding) favors SLD's rising patient implant volumes. Yield on cost (R&D yield) favors MOBI, generating market capture without fighting established goliaths. (R&D yield shows innovation efficiency). Pricing power is strong for both due to FDA breakthrough metrics. Cost programs are a focus for both to survive the "profitability horizon". Refinancing/maturity wall risks are low for SLD post-IPO, but high for MOBI. ESG/regulatory tailwinds are even. Overall Growth outlook winner: MOBI, strictly due to its lack of direct competition. Fair Value metrics show both companies punished for their cash burn. P/E and EV/EBITDA are both N/A due to lack of profits. (P/E measures price against profit; EV/EBITDA measures firm value against cash earnings). P/AFFO is N/A and the implied cap rate is 0%. Looking at NAV premium/discount (measured via Price-to-Sales), SLD's massive stock drop has compressed its forward multiple to roughly 3x sales, making it significantly cheaper than MOBI's 8.5x premium. (A lower Price-to-Sales multiple indicates a cheaper valuation). Dividend yield & payout/coverage is 0% for both. Quality vs price note: SLD is a heavily discounted IPO that the market rejected, whereas MOBI holds its premium by executing in an uncrowded space. Better value today: SLD, strictly on a multiple basis. Winner: MOBI over SLD based on competitive positioning and market sentiment. While Saluda Medical boasts a freshly capitalized balance sheet and trades at a much cheaper multiple following its -45% IPO crash, it faces the unenviable task of fighting entrenched corporate giants in the spinal cord stimulation market. MOBI's key strengths—>100% revenue growth and an uncrowded stroke rehabilitation TAM—make it a far more attractive growth story. SLD's notable weakness is the extreme public market skepticism surrounding its path to profitability, making MOBI the better risk-adjusted momentum play.

Mobia Medical, Inc. (MOBI) Competitive Analysis

Executive Summary

Comprehensive Analysis

Competitor Details

NeuroPace, Inc.

BrainsWay Ltd.

CVRx, Inc.

electroCore, Inc.

Neuronetics, Inc.

Saluda Medical